BeStock  
Stocks › Biotechnology › ATTO

Attovia Therapeutics ATTO

US equityMarket cap rank #3395Biotechnology
$15.10 −$0.48 (-3.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $15.10 0.00%
Open$15.40
Prev close$15.58
Day range$14.80 – $15.46
Volume372.2K
Market cap$690.26M
P/E (TTM)–
Dividend yield–

ATTO Stock News

Headlines matching Attovia Therapeutics or the ATTO ticker, most recent first.

  • LifeSci Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45Market news · 5 Sep 2026 · Direct mention
  • Citi Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $30Market news · 4 Sep 2026 · Direct mention
  • Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)TipRanks · 4 Sep 2026 · Direct mention
  • Morgan Stanley Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $39Market news · 3 Sep 2026 · Direct mention
  • Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO)TipRanks · 3 Sep 2026 · Direct mention
  • RBC Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45Market news · 3 Sep 2026 · Direct mention
  • U.S. Stocks Move | Biotech Company Attovia Therapeutics (ATTO.US) Debuts on Nasdaq, Closing Up 28.82% on First Trading DayZhitong Finance · 6 Aug 2026 · Direct mention
  • LifeSci Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45Market news · 31 Aug 2026 · Direct mention
  • RBC Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45Market news · 31 Aug 2026 · Direct mention
  • Morgan Stanley Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $39Market news · 31 Aug 2026 · Direct mention
  • Citi Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $30Market news · 31 Aug 2026 · Direct mention
  • Goldman Sachs-backed immunotherapy startup Attovia (ATTO.US) files for Nasdaq listing: aiming to raise up to $212.5 million, becoming the latest addition to the biotech IPO boom PositiveZhitong Finance · 30 Jul 2026 · Direct mention
  • Attovia Says Phase 1b ATTO-1310 Gave 82% Of Chronic Itch Patients 4-Point Relief At Week 12 Vs. 22% On Placebo; Atopic Dermatitis Itch Response 44% Vs. 75% PlaceboBenzinga · 6 Nov 2026 · Direct mention
  • RBC Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45Market news · 10 Nov 2026 · Direct mention
  • Citi Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Raises Target Price to $34 PositiveMarket news · 10 Nov 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on ATTO.

Sign in to join the discussion.

Scroll to Top